Proposed Escalation Strategy A theoretical cagrilintide and retatrutide combination protocol might follow this gradual escalation approach: Weeks 1-4: Foundation Phase Cagrilintide: 0.6 mg weekly Retatrutide: 2 mg weekly Focus: Establishing tolerance to both compounds Monitoring: Gastrointestinal effects, appetite changes Weeks 5-8: Escalation Phase Cagrilintide: 1.2 mg weekly Retatrutide: 4 mg weekly Focus: Increasing receptor activation Monitoring: Weight changes, metabolic markers Weeks 9-12: Optimization Phase Cagrilintide: 2.4 mg weekly Retatrutide: 8 mg weekly Focus: Approaching therapeutic targets Monitoring: Comprehensive metabolic assessment Weeks 13+: Maintenance Phase Cagrilintide: 3.0-4.5 mg weekly Retatrutide: 8-12 mg weekly Focus: Sustained metabolic effects Monitoring: Long-term safety and efficacy This graduated approach mirrors the successful strategies used in cagrilintide 10mg research protocols, where slow escalation minimizes side effects while building therapeutic benefit
However, a B12 shot is a simple, straightforward way of boosting a patients vitamin levels with perfect accuracy
Piatti PM, Monti LD, Valsecchi G, Magni F, Setola E, Marchesi F, Galli-Kienle M, Pozza G, Alberti KG
Pricing sat well below what compounding pharmacies charged for similar products
Protocol 4: degenerative disc disease and facet arthritis (advanced) Goal: Slow degenerative processes and support tissue quality in chronic spinal degeneration Peptides: BPC-157 : 500mcg twice daily ongoing GHK-Cu : 2mg daily for tissue regeneration KPV : 300mcg daily for anti-inflammatory effects Optional : TB-500 2mg weekly for systemic support Duration: Extended protocols, potentially cycling on and off Why this works: Degenerative conditions require ongoing support rather than acute treatment
